Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

Table 6 Multivariate analysis of OS for second-line treatment in advanced ESCC patients

Characteristics	Multivariate Analysis
Characteristics	HR	95CI	P
PNI After 2 Cycles (≥ 45 vs. <45)	1.633	0.898 ∼ 2.969	0.108
ORR (CR + PR vs. SD + PD)	0.278	0.120 ∼ 0.642	0.003
DCR (CR + PR + SD vs. PD)	0.873	0.477 ∼ 1.594	0.658
Treatment Plan(Camrelizumab Combined Chemotherapy vs. Chemotherapy)	0.395	0.218 ∼ 0.713	0.002

ISSN: 1477-7819